Saturday 17 October 2026
Export PYPD’s income statement to Excel — free account
PolyPid Ltd.
PYPD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.1%, free cash flow fell 65.0% and total debt fell 88.4%, each against the same quarter a year earlier.
4.75
0.15
−3.06%
Follow PYPD
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 259.20 | 162.00 | 19.50 | 3.57 | 2.37 | 2.30 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 583.50 | 495.00 | 207.00 | 38.70 | 9.20 | 4.63 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 58 | 69 | 79 | 69 | 79 | 61 | 62 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (11) | (54) | 6 | (7) | (37) | (43) | (39) | (24) | (29) | (34) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (11) | 0 | 6 | (7) | (37) | (43) | (40) | (24) | (29) | (34) | |||||
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (1.05) | (4.45) | 316.67 | (368.67) | (122.22) | (67.87) | (60.96) | (16.99) | (4.91) | (2.09) | |||||
| Cash flow | (0.73) | (0.93) | (891.87) | (928.24) | (67.68) | (51.95) | (52.99) | (12.27) | (3.71) | (1.70) | |||||
| Capex | 0.00 | 0.00 | (164.38) | (47.01) | (2.45) | (4.26) | (2.73) | (0.14) | (0.01) | (0.01) | |||||
| Free cash flow | (0.73) | (0.93) | (1,056.26) | (975.24) | (70.13) | (56.21) | (55.72) | (12.41) | (3.73) | (1.72) | |||||
| Book value | 0.76 | (2.16) | (4,369.52) | 998.98 | 228.07 | 57.68 | 9.00 | (1.49) | 1.30 | 0.67 | |||||
| Shares, m | 13 | 13 | 0 | 0 | 0 | 1 | 1 | 1 | 6 | 16 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (10) | (12) | (17) | (17) | (22) | (32) | (34) | (17) | (22) | (28) | ||||
| Capex | (1) | (2) | (3) | (1) | (1) | (3) | (2) | 0 | 0 | 0 | |||||
| Free cash flow | (10) | (12) | (20) | (18) | (22) | (35) | (36) | (17) | (22) | (28) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 17 | 15 | 4 | 25 | 44 | 27 | 6 | (1) | 4 | 7 | ||||
| Total debt | — | — | — | — | — | — | 12 | 10 | 7 | 1 | |||||
| Net debt | (18) | (18) | (8) | (27) | (45) | (33) | (2) | 5 | (8) | (12) | |||||
| Shareholders’ equity | 10 | (29) | (82) | 19 | 73 | 36 | 6 | (2) | 8 | 11 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (66.32) | (614.88) | 35.09 | (28.63) | (78.31) | (70.95) | (112.69) | (115.45) | (142.99) | (143.79) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (58.83) | (802.55) | (562.36) | (533.88) | 0.00 | 0.00 | |||||
| ROE | 22.84 | 96.48 | (6.95) | 8.16 | 577.80 | (78.36) | (189.32) | (1,278.60) | (1,038.73) | (366.29) | |||||
Negative figures in brackets.
Charts ten years each
PolyPid Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| COYA Coya Therapeutics, Inc. | $101.8M | — (loss-making) | — (loss-making) | +48.96% (above 0%: growing) | n/m | −27.79% (below 0%: shrinking) | 100.00% | (2,891.67%) | Compare |
| UNCY Unicycive Therapeutics, Inc. | $100.0M | — (loss-making) | — (loss-making) | — | n/m | +9.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDTX Black Diamond Therapeutics, Inc. | $100.0M | — (loss-making) | — (loss-making) | — | n/m | +12.91% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PYPD PolyPid Ltd. | $99.5M | — (loss-making) | — | — | n/m | −64.96% (below 0%: shrinking) | 0.00% | 0.00% | |
| MIST Milestone Pharmaceuticals Inc. | $98.9M | — (loss-making) | — (loss-making) | −62.73% (below 0%: shrinking) | n/m | −80.81% (below 0%: shrinking) | 94.28% | (4,584.97%) | Compare |
| CBUS Cibus, Inc. | $98.6M | — (loss-making) | — (loss-making) | +6.54% (above 0%: growing) | n/m | +31.62% (above 0%: growing) | 100.00% | (1,300.30%) | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $97.4M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NRXS Neuraxis, Inc. | $97.2M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| IMUX Immunic, Inc. | $96.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $98.8M | — | — | +27.75% | — | +11.34% | 90.07% | (55.08%) |
PolyPid Ltd. (PYPD) key facts
- PolyPid Ltd. (PYPD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PYPD traded at $4.75, a market capitalization of $99.5 million.
- Return on equity was −366.3% and debt-to-equity 0.00.